Mirati Therapeutics (MRTX) Tops Q3 EPS by $1.24; Reports Cash and Cash Equivalents of $1.2B

Mirati Therapeutics (NASDAQ: MRTX) reported Q3 EPS of ($1.55), $1.34 better than the analyst estimate of ($2.89). Revenue for the quarter came in at $71.7 million versus the consensus estimate of $10.62 million.

For earnings history and earnings-related data on Mirati Therapeutics (MRTX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15